CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 1,013 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01117480
NCT01117480N/ACompleted
CompareCT.gov

Real Life Evaluation of Rheumatoid Arthritis in Canadians Taking HUMIRA (REACH)

AbbVie (prior sponsor, Abbott)·observational·Posted May 5, 2010·Updated Feb 24, 2016

In Brief

An observational study for Moderate-to-severe Rheumatoid Arthritis. Completed, enrolled 1,013 participants.

Detailed Summary

The purpose of this study is to evaluate the clinical effectiveness and safety of adalimumab as used in routine clinical practice in adult participants with moderate to severe rheumatoid arthritis (RA) in Canada.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsModerate-to-severe Rheumatoid Arthritis
Countries--
CollaboratorsUniversity Health Network, Toronto

Timeline

N/ACompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMay 5, 2010
Enrollment StartJul 1, 2005
Primary CompletionDec 1, 2014
TodayJul 2, 2026
Enrollment to primary: 9.4 yearsPosted 16.2 years ago